Found: 2950
Select item for more details and to access through your institution.
Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
- Published in:
- 2024
- By:
- Publication type:
- Editorial
Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Analytical and diagnostic performance of Theradiag i-Tracker assays on IDS-iSYS for infliximab and adalimumab therapeutic drug monitoring.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Clinical Guide to Navigating the Landscape of Biosimilars for Inflammatory Bowel Disease.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, n. 7, p. 376
- By:
- Publication type:
- Article
Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?
- Published in:
- Rheumatology, 2024, v. 63, n. 7, p. 1957, doi. 10.1093/rheumatology/kead515
- By:
- Publication type:
- Article
Osteitis in long bones of SAPHO syndrome mimicking osteosarcoma.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 12, p. 1510, doi. 10.1111/apt.18000
- By:
- Publication type:
- Article
An 18-Year-Old Man With a Great Toe Lesion.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Safety and Efficacy of Inpatient Infliximab Rescue Therapy for Acute Crohn's Disease Flares.
- Published in:
- American Surgeon, 2024, v. 90, n. 6, p. 1591, doi. 10.1177/00031348241246160
- By:
- Publication type:
- Article
Transitioning patients from intravenous to subcutaneous infliximab and vedolizumab for inflammatory bowel disease: what is the opportunity cost of improving access to healthcare?
- Published in:
- Internal Medicine Journal, 2024, v. 54, n. 6, p. 970, doi. 10.1111/imj.16311
- By:
- Publication type:
- Article
Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 3, p. 841, doi. 10.1007/s40744-024-00653-6
- By:
- Publication type:
- Article
Case report: Inflammatory sternoclavicular joint arthritis induced by an immune checkpoint inhibitor with remarkable responsiveness to infliximab.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1400097
- By:
- Publication type:
- Article
Effectiveness and safety of a third‐line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 10, p. 1248, doi. 10.1111/apt.17938
- By:
- Publication type:
- Article
Infliximab monitoring in Crohn's disease: a neural network approach for evaluating disease activity and immunogenicity.
- Published in:
- Therapeutic Advances in Gastroenterology, 2024, p. 1, doi. 10.1177/17562848241251949
- By:
- Publication type:
- Article
Successful Fistula Closure After Treatment with Colostomy and Infliximab in a Patient with Ulcerative Colitis Complicated by Rectovaginal Fistula.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 769, doi. 10.1093/bjd/ljae042
- By:
- Publication type:
- Article
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
- Published in:
- Digestive Diseases & Sciences, 2024, v. 69, n. 5, p. 1808, doi. 10.1007/s10620-023-08252-1
- By:
- Publication type:
- Article
The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model.
- Published in:
- Pediatric Drugs, 2024, v. 26, n. 3, p. 331, doi. 10.1007/s40272-024-00621-1
- By:
- Publication type:
- Article
Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data.
- Published in:
- Health Economics Review, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13561-024-00507-5
- By:
- Publication type:
- Article
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.
- Published in:
- Clinical Pharmacokinetics, 2024, v. 63, n. 4, p. 529, doi. 10.1007/s40262-024-01354-7
- By:
- Publication type:
- Article
Efficacy and safety of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
- Published in:
- European Journal of Pediatrics, 2024, v. 183, n. 4, p. 1765, doi. 10.1007/s00431-024-05437-2
- By:
- Publication type:
- Article
Journal scan.
- Published in:
- Gastrointestinal Nursing, 2024, v. 22, n. 3, p. 138, doi. 10.12968/gasn.2024.22.3.138
- By:
- Publication type:
- Article
Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis.
- Published in:
- Journal of Clinical Pharmacology, 2024, v. 64, n. 4, p. 399, doi. 10.1002/jcph.2384
- By:
- Publication type:
- Article
Infliximab Concentrations in Participants with Moderate to Severe COVID‐19.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Effectiveness and safety of vedolizumab and infliximab in biologic‐naïve patients with moderate‐to‐severe ulcerative colitis: A multicenter, retrospective cohort study.
- Published in:
- Journal of Digestive Diseases, 2024, v. 25, n. 4, p. 230, doi. 10.1111/1751-2980.13270
- By:
- Publication type:
- Article
Simulated cost‐effectiveness of a novel precision‐guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
- Published in:
- Pharmacotherapy, 2024, v. 44, n. 4, p. 331, doi. 10.1002/phar.2915
- By:
- Publication type:
- Article
Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients.
- Published in:
- Respiratory Research, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s12931-024-02758-6
- By:
- Publication type:
- Article
CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn's disease.
- Published in:
- Insights into Imaging, 2024, v. 15, n. 1, p. 1, doi. 10.1186/s13244-024-01637-4
- By:
- Publication type:
- Article
Biologics in Focus: A Comprehensive Review of the Current Biological Therapies for Ulcerative Colitis in the United Arab Emirates (UAE).
- Published in:
- Gastrointestinal Disorders, 2024, v. 6, n. 1, p. 241, doi. 10.3390/gidisord6010018
- By:
- Publication type:
- Article
VEXAS syndrome with granulomatosis with polyangiitis manifestation: retained in remission using methotrexate and infliximab.
- Published in:
- Rheumatology, 2024, v. 63, n. 3, p. e110, doi. 10.1093/rheumatology/kead536
- By:
- Publication type:
- Article
Analysis of the risk of future gastrointestinal surgery in Crohn's disease with stricture.
- Published in:
- Saudi Journal of Gastroenterology, 2024, v. 30, n. 2, p. 108, doi. 10.4103/sjg.sjg_256_23
- By:
- Publication type:
- Article
Highly sensitive therapeutic drug monitoring of infliximab in serum by targeted mass spectrometry in comparison to ELISA data.
- Published in:
- Clinical Proteomics, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12014-024-09464-x
- By:
- Publication type:
- Article
Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH‐LT study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 4, p. 526, doi. 10.1111/apt.17822
- By:
- Publication type:
- Article
Immortal Time Bias for Infliximab in Central Nervous System Tuberculosis.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Reply to Khan et al.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Longitudinal Measurements of Blood Biomarkers in Patients with Crohn's Disease or Ulcerative Colitis Treated with Infliximab: Only the Latest Values in the Induction Period Predict Treatment Failure.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 4, p. 926, doi. 10.3390/jcm13040926
- By:
- Publication type:
- Article
Constructing models for Crohn's disease diagnosis and prediction of infliximab non-response based on angiogenesisrelated genes.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1239496
- By:
- Publication type:
- Article
British Society of Rheumatology guideline working group response to European Medicines Agency safety update on Hydroxychloroquine.
- Published in:
- 2024
- By:
- Publication type:
- Letter to the Editor
Construction of a molecular inflammatory predictive model with histone modification-related genes and identification of CAMK2D as a potential response signature to infliximab in ulcerative colitis.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1282136
- By:
- Publication type:
- Article
Use of double-balloon endoscopy and an endoscopic scoring system to assess endoscopic remission in isolated small bowel Crohn's disease after treatment with infliximab.
- Published in:
- Therapeutic Advances in Gastroenterology, 2024, p. 1, doi. 10.1177/17562848231224842
- By:
- Publication type:
- Article
Direct transition from rapid-infusion originator to rapid-infusion biosimilar tumor necrosis factor inhibitor in children with inflammatory bowel disease: A case series.
- Published in:
- American Journal of Health-System Pharmacy, 2024, v. 81, n. 2, p. 61, doi. 10.1093/ajhp/zxad217
- By:
- Publication type:
- Article
Racial Disparities in Infliximab Efficacy for Ulcerative Colitis: Evidence Synthesis and Effect Modification Assessment.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 2, p. 319, doi. 10.3390/jcm13020319
- By:
- Publication type:
- Article
Anti-TNF.
- Published in:
- Gastroenterology & Hepatology, 2024, v. 20, p. 3
- Publication type:
- Article
Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.
- Published in:
- Pediatric Rheumatology, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12969-023-00941-5
- By:
- Publication type:
- Article
Recurrence of Drug-Induced Lupus Secondary to Vedolizumab Use in a Patient With Crohn's Disease.
- Published in:
- ACG Case Reports Journal, 2024, v. 11, n. 1, p. 1, doi. 10.14309/crj.0000000000001270
- By:
- Publication type:
- Article
Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 1, p. 140, doi. 10.1111/apt.17770
- By:
- Publication type:
- Article
Letter: Comparing first‐line infliximab and vedolizumab for ulcerative colitis—it depends on how you use the drug. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 59, n. 1, p. 142, doi. 10.1111/apt.17796
- By:
- Publication type:
- Article
Infliximab, a Monoclonal Antibody against TNF-α, Inhibits NF-κB Activation, Autotaxin Expression and Breast Cancer Metastasis to Lungs.
- Published in:
- Cancers, 2024, v. 16, n. 1, p. 52, doi. 10.3390/cancers16010052
- By:
- Publication type:
- Article
Infliximab-induced amicrobial pustulosis of the folds in a patient with Crohn disease.
- Published in:
- Dermatology Online Journal, 2024, v. 30, n. 1, p. 1, doi. 10.5070/D330163286
- By:
- Publication type:
- Article
Point-of-Care Assays for Infliximab Therapeutic Drug Monitoring in Patients with IBD: Is Quicker Better?
- Published in:
- Digestive Diseases & Sciences, 2024, v. 69, n. 1, p. 5, doi. 10.1007/s10620-023-08140-8
- By:
- Publication type:
- Article